Bicara Therapeutics Inc. Logo

Bicara Therapeutics Inc.

Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.

BCAX | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
116 HUNTINGTON AVENUE SUITE 703, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class bifunctional therapies for patients with solid tumors. The company engineers advanced biologics designed to combine the precision of a validated tumor-targeting agent with the power of a tumor microenvironment modulator. This dual-action approach aims to deliver more effective and durable anti-tumor responses. Bicara's pipeline is dedicated to advancing these innovative targeted treatments to address significant unmet needs in oncology, with a focus on indications such as head and neck cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Bicara Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bicara Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bicara Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea
014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America
KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan
4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan
4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia
KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America
KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea
307750
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea
009290
Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine
KMED

Talk to a Data Expert

Have a question? We'll get back to you promptly.